Mark Avagliano

2022

In 2022, Mark Avagliano earned a total compensation of $1.1M as Chief Business Officer at G1 Therapeutics, a 25% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$154,382
Option Awards$380,207
Salary$465,005
Stock Awards$128,280
Other$9,150
Total$1,137,024

Avagliano received $465K in salary, accounting for 41% of the total pay in 2022.

Avagliano also received $154.4K in non-equity incentive plan, $380.2K in option awards, $128.3K in stock awards and $9.2K in other compensation.

Rankings

In 2022, Mark Avagliano's compensation ranked 2,783rd out of 5,736 executives tracked by ExecPay. In other words, Avagliano earned more than 51.5% of executives.

ClassificationRankingPercentile
All
2,783
out of 5,736
52nd
Division
Manufacturing
1,550
out of 3,125
50th
Major group
Chemicals And Allied Products
719
out of 1,416
49th
Industry group
Drugs
671
out of 1,317
49th
Industry
Pharmaceutical Preparations
485
out of 963
50th

Pay ratio

Mark Avagliano's Pay$1,137,024
Median Employee's Pay$243,930
Pay Ratio

5

to 1

In 2022, the annual total compensation of Mark Avagliano was $1,137,024.

The annual total compensation of the median employee at G1 Therapeutics was $243,930.

The ratio of Mark Avagliano's pay to the pay of median employee was therefore 5 to one.

Source: SEC filing on April 26, 2023.

Avagliano's colleagues

We found two more compensation records of executives who worked with Mark Avagliano at G1 Therapeutics in 2022.

2022

John Bailey

G1 Therapeutics

Chief Executive Officer

2022

Jennifer Moses

G1 Therapeutics

Chief Financial Officer

News

You may also like